By admin 
CureSearch for Children’s Cancer, a national nonprofit foundation dedicated to accelerating the development of safe and effective treatments for pediatric cancer, has officially announced the appointment of Mark Zafra to its Board of Directors. This strategic addition comes at a pivotal time for the organization as it seeks to bridge the gap between laboratory research and clinical application. Zafra, a distinguished executive with over twenty years of experience in global supply chain management and strategic procurement, currently serves as the Chief Procurement Officer at LiveRamp. His appointment signals a commitment by CureSearch to integrate high-level corporate expertise into the nonprofit sector, specifically focusing on operational efficiency and the scaling of research initiatives.
The selection of Zafra is noteworthy not only for his professional pedigree but also for his personal connection to the cause. As a cancer survivor reaching a significant 20-year milestone since his initial diagnosis, Zafra brings a unique perspective that combines the analytical rigor of a corporate leader with the lived experience of a patient. This dual perspective is expected to drive CureSearch’s mission to ensure that every child diagnosed with cancer has access to innovative treatment options that minimize long-term side effects and maximize survival rates.
Professional Trajectory and Strategic Expertise
Mark Zafra’s professional background is characterized by a series of leadership roles at some of the world’s most influential technology and healthcare companies. At LiveRamp, he oversees a comprehensive portfolio that includes global strategic sourcing, purchasing, travel, and accounts payable. His role is central to the company’s operational stability and fiscal health, requiring a deep understanding of complex global markets and the ability to navigate intricate vendor ecosystems.
Prior to his tenure at LiveRamp, Zafra held transformative leadership positions at Twitter, where he was instrumental in scaling procurement operations during periods of rapid international expansion. His career also includes significant tenures at Allianz Fireman’s Fund, McKesson, HP, and Agilent Technologies. In these roles, Zafra was frequently tasked with leading large-scale transformation initiatives aimed at driving innovation and efficiency. His expertise in supply chain management is particularly relevant to the nonprofit medical sector, where the "supply chain" of drug development—from initial discovery through clinical trials to regulatory approval—is often fraught with logistical and financial bottlenecks.
By bringing a Chief Procurement Officer into its board structure, CureSearch aims to apply private-sector methodologies to the "Valley of Death" in pediatric drug development. This term refers to the phase where promising research often stalls due to a lack of funding or strategic direction before it can reach clinical trials. Zafra’s experience in resource optimization and strategic partnerships is expected to provide CureSearch with the tools necessary to navigate these challenges more effectively.
The Landscape of Pediatric Cancer Research
The urgency of Zafra’s appointment is underscored by the current state of pediatric oncology in the United States. While survival rates for some forms of childhood cancer have improved significantly over the last few decades, cancer remains the leading cause of death by disease for children in the U.S. Each year, approximately 15,000 children and adolescents are diagnosed with cancer, and for many rare or aggressive forms, treatment options remain outdated and highly toxic.
A critical issue facing the field is the disparity in research funding. According to data from the National Cancer Institute (NCI), only about 4% of federal funding for cancer research is specifically allocated to pediatric cancers. The pharmaceutical industry also faces a "market failure" in this sector; because childhood cancers are considered orphan diseases with a relatively small patient population compared to adult cancers, there is often less financial incentive for private companies to invest in pediatric-specific drug development.
CureSearch for Children’s Cancer operates within this gap. The organization focuses on funding "bench-to-bedside" research, prioritizing projects that have a clear path to clinical trials. Since its inception, CureSearch has been a catalyst for progress, but the complexity of modern biotechnology requires increasingly sophisticated oversight. The addition of a board member with Zafra’s background in procurement and global operations is a move toward more disciplined, results-oriented philanthropy.
A Personal Mission: From Survivorship to Advocacy
Mark Zafra’s commitment to the organization is deeply rooted in his personal history. In 2024, Zafra marks 20 years since his first cancer diagnosis, a milestone that serves as both a celebration of resilience and a call to action. His journey as a survivor provides him with an intrinsic understanding of the stakes involved in cancer research—not just in terms of survival statistics, but in the quality of life for those who undergo treatment.
"It is with great enthusiasm and a deep sense of responsibility that I join CureSearch’s Board of Directors," Zafra stated in a release regarding his appointment. "As a survivor myself, I am a passionate advocate for advancing cancer research and am honored by the opportunity to contribute my skills and experience to a mission that matters deeply to me."
This personal narrative extends to Zafra’s active participation in CureSearch’s community initiatives. Later this year, he will participate in the CureSearch Ultimate Hike in Jackson, Wyoming. The Ultimate Hike is the organization’s signature endurance fundraising program, challenging participants to complete a 20-plus mile trek in a single day. For Zafra, the hike is more than a physical challenge; it is a symbolic representation of the arduous journey patients face and a tangible way to raise critical funds for cutting-edge research.
Organizational Impact and Leadership Synergy
The leadership at CureSearch has expressed high expectations for the impact Zafra will have on the board’s strategic direction. Jared Brancazio, the CureSearch Board Chair, highlighted the intersection of Zafra’s professional skills and his personal dedication as a primary factor in his selection.
"Mark’s professional leadership and personal commitment to advancing cancer research make him an incredible addition to the CureSearch Board," Brancazio said. "We’re honored to have him help guide our work and accelerate our impact."
Zafra’s role on the board will likely involve overseeing financial governance, advising on strategic partnerships, and helping the organization refine its operational model. In an era where donors are increasingly looking for transparency and measurable impact, having a board member who specializes in procurement and efficiency can enhance the organization’s credibility and attract larger institutional donors.
Chronology of Leadership and Innovation
To understand the trajectory that led to this appointment, one must look at the evolution of CureSearch’s board and its strategic focus over the last decade.
- 2012–2015: CureSearch shifted its focus toward funding research that specifically addresses the "Valley of Death," moving away from broad academic grants toward targeted clinical trial support.
- 2018–2021: The organization increased its emphasis on industry partnerships, recognizing that collaboration with biotech companies is essential for moving drugs through the FDA pipeline.
- 2022–2023: A search began for board members who could offer expertise in global logistics and strategic sourcing, reflecting the global nature of modern clinical trials and the need for efficient resource allocation.
- 2024: Mark Zafra is appointed to the board, coinciding with his 20th anniversary as a survivor and the launch of new initiatives in precision medicine for pediatric oncology.
This chronology demonstrates a deliberate move toward a "venture philanthropy" model, where the nonprofit acts as a strategic investor in the most promising medical advancements.
Broader Implications for the Nonprofit Sector
The appointment of a Chief Procurement Officer to a major medical nonprofit board reflects a broader trend in the philanthropic world. Organizations are increasingly looking beyond traditional "philanthropists" or medical doctors to fill their boards. There is a growing demand for "operational experts"—individuals who understand how to manage large budgets, negotiate complex contracts, and streamline global operations.
In the context of pediatric cancer, this is particularly vital. The development of a single new drug can cost upwards of $2 billion and take over a decade. For pediatric drugs, the timeline is often longer and the funding scarcer. By applying the principles of strategic sourcing and procurement, CureSearch can potentially reduce the "cost of innovation," ensuring that a higher percentage of every donated dollar goes directly toward research and patient outcomes.
Furthermore, Zafra’s background in the tech sector (Twitter, LiveRamp) brings a culture of agility and data-driven decision-making to the board. As pediatric oncology moves toward genomic sequencing and personalized medicine, the ability to manage and leverage data becomes a central component of the research process.
Conclusion: A New Era of Targeted Research
As CureSearch for Children’s Cancer welcomes Mark Zafra, the organization reinforces its position as a forward-thinking leader in the fight against pediatric disease. The integration of Zafra’s supply chain expertise with his personal advocacy as a survivor creates a powerful catalyst for change.
The upcoming Ultimate Hike in Jackson, Wyoming, will serve as an early milestone in Zafra’s tenure, bridging the gap between high-level board governance and grassroots community engagement. For the thousands of families currently navigating a pediatric cancer diagnosis, the addition of a leader who understands both the "business" of research and the "reality" of the disease offers a renewed sense of hope.
Through strategic leadership, rigorous financial oversight, and a personal commitment to the cause, Zafra and the CureSearch Board are poised to accelerate the delivery of the next generation of cancer treatments. The ultimate goal remains clear: a world where every child can survive cancer and lead a long, healthy life, free from the toxic side effects of outdated therapies. With this new appointment, CureSearch moves one step closer to making that vision a reality.
